Global Endometrial Cancer Market Research Report, by Diagnosis (Pelvic Examination, Transvaginal Ultrasound, Endometrial Biopsy), Treatment (Hysterectomy, Radiation), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2027
Market Highlights
The endometrial cancer market is expected to witness tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of endometrial cancer. However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.
Segmentation
The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and diagnostic laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin and, cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6226
Regional Analysis
The Americas is expected to dominate the endometrial cancer market during the forecast period. The increasing occurrence of ovarian cancer drives the market in this region. The American Cancer Society estimated that in 2018, 22,240 women are likely to be diagnosed with ovarian cancer. This is expected to influence the market growth during the forecast period.
Europe (UK, Belgium, France, and the Netherlands) is the second largest in the market owing to the increasing prevalence of obesity and growing healthcare expenditure. According to WHO, 23% of the women in Europe were obese in 2014.
Asia-Pacific was projected to be the fastest growing region for the global endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. The Asian Diabetes Prevention Initiative estimated that by 2030 India and China would have a diabetic patient pool with a total of half billion people. This is expected to provide favorable backgrounds for the market to grow.
The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.
Key Players
Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/endometrial-cancer-market-6226
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Global Endometrial Cancer Market Research Report, by Diagnosis (Pelvic Examination, Transvaginal Ultrasound, Endometrial Biopsy), Treatment (Hysterectomy, Radiation), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2023Market HighlightsThe endometrial cancer market is expected to witness tremendous growth owing to the rising prevalence of endometrial cancer.
Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market.
Diabetes is another risk factor that leads to the development of endometrial cancer.
However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.SegmentationThe global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user.
The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors.
The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin and, cisplatin.
Global Endometrial Cancer Market Research Report, by Diagnosis (Pelvic Examination, Transvaginal Ultrasound, Endometrial Biopsy), Treatment (Hysterectomy, Radiation), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2023Market HighlightsThe endometrial cancer market is expected to witness tremendous growth owing to the rising prevalence of endometrial cancer.
Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market.
Diabetes is another risk factor that leads to the development of endometrial cancer.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/6226However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.SegmentationThe global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user.
The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors.
The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin and, cisplatin.
On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
The rising incidence of cancer, technological advancements such as the introduction of mobile IORT system, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market.
Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.The Electron IORT segment to account for the largest share of the intraoperative radiation therapy market, by method, in 2019Based on method, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy.
The electron IORT segment is expected to account for the largest share of the intraoperative radiation therapy market in 2019.
The large share of this segment can be attributed to its advantages such as better depth dose distribution, low treatment time, and optimal dose homogeneity as compared to HDR-IORT or kV IORT.Download PDF Brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083The other cancers segment, by application, is to register the highest CAGR in the intraoperative radiation therapy market during the forecast periodBased on application, the intraoperative radiation therapy market is segmented into breast cancer, brain tumor, gastrointestinal cancer, head & neck cancer, and other cancers.
The other cancer application segment includes penile cancer, lung cancer, childhood cancer, colorectal cancer, endometrial & cervical cancer, and prostate cancer.
This segment is expected to grow at the fastest CAGR owing to growing research activities in new application areas of the IORT market.North America to dominate the intraoperative radiation therapy market during the forecast periodThe intraoperative radiation therapy market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.
Endometrial Cancer Treatment in India.
An endometrial tumour is the most well-known type of uterine cancer.
Since the endometrium (inner epithelial layer) is a part of the uterus, an endometrial disease is frequently alluded to as uterine cancer.
Symptoms: Difficult or painful urination, Persistent pain in the pelvic area, Book Doctor's Appointment Online.
The isoflavones in tofu are well known to be beneficial in reducing cancer risks.
Research on soy intake and endometrial cancer suggests that a higher consumption of products such as tofu may reduce the risk of endometrial cancer in post-menopausal women.
Tofu has also been associated with a reduction in breast, lung, and prostate cancer.
Here we are talking about Tofu Good for You in details.
